Tenosynovial Giant Cell Tumour — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Soft tissue and juxtaarticular tumors of the knee.
Walker Eric A et al. — Skeletal radiology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/41706083/
- 2.
Localized Tenosynovial Giant Cell Tumors and Indicators of Surgical Recurrence.
Hurst Lawrence C et al. — Journal of hand surgery global online (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42027752/
- 3.
Management of tenosynovial giant cell tumor: approved and investigational therapies.
Conway Alexander P et al. — Expert review of anticancer therapy (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/41557367/
- 4.
Diagnostic Assessment and Surgical Management of Synovial Chondromatosis of the Midfoot in a 13-Year-Old Child.
Klauss Julia et al. — HSS journal : the musculoskeletal journal of Hospital for Special Surgery (10 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42292062/
- 5.
Prefrontal parvalbumin neurons mediate working memory in a task demand-dependent manner.
Dexter Tyler D et al. — Nature communications (10 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42265093/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Active (not recruiting) — Phase 1 — Deciphera Pharmaceuticals, LLC
https://clinicaltrials.gov/study/NCT03069469
- 2.
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Completed — Phase 4 — Daiichi Sankyo
https://clinicaltrials.gov/study/NCT04526704
- 3.
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Completed — Phase 3 — Daiichi Sankyo
https://clinicaltrials.gov/study/NCT02371369
- 4.
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Active (not recruiting) — Phase 3 — Deciphera Pharmaceuticals, LLC
https://clinicaltrials.gov/study/NCT05059262
- 5.
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
Completed — Phase 2 — AmMax Bio, Inc.
https://clinicaltrials.gov/study/NCT05349643
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Tenosynovial Giant Cell Tumour
Tenosynovial Giant Cell Tumour (TGCT) is a rare, locally aggressive tumour arising from the synovial tissue of joints, tendon sheaths, and bursae. It occurs in two subtypes: localised (a tumour with a distinct, contained boundary) and diffuse (infiltrative growth without a clear boundary, which can destroy surrounding cartilage and bone). The diffuse subtype frequently recurs after surgery. Targeted therapies blocking the CSF1/CSF1R pathway have become an important treatment option for disease that cannot be fully removed surgically.
Most Recent Research
While the wide spectrum of soft tissue neoplasms found throughout the body may occur at the knee, this review focuses on the more commonly encountered intraarticular or juxtaarticular solid soft tissue lesions that may be encountered in this location. The benign intraarticular synovial-based tumors or tumor-like processes of tenosynovial giant cell tumor, synovial chondromatosis, and lipoma arborescens are reviewed, as are the solid juxtaarticular neoplasms of nerve sheath tumors, synovial sarcoma, and myxoid liposarcoma. Several uncommon lesions that occur at the knee while relatively rare elsewhere are also discussed and include synovial vascular malformations, the Hoffa fat pad chondroma, and popliteal arterial cystic adventitial disease. Finally, clear cell sarcoma, a rare malignancy which originates in ligaments and tendons, has the knee as the second most common site of occurrence and may be misinterpreted as a benign entity or sequelae of injury, is reviewed.
Common Questions
What is Tenosynovial Giant Cell Tumour?
Tenosynovial Giant Cell Tumour (TGCT) is a rare, locally aggressive tumour arising from the synovial tissue of joints, tendon sheaths, and bursae. It occurs in two subtypes: localised (a tumour with a distinct, contained boundary) and diffuse (infiltrative growth without a clear boundary, which can destroy surrounding cartilage and bone). The diffuse subtype frequently recurs after surgery. Targeted therapies blocking the CSF1/CSF1R pathway have become an important treatment option for disease that cannot be fully removed surgically.
How many clinical trials are available for Tenosynovial Giant Cell Tumour?
RareWays currently indexes 24 clinical trials for Tenosynovial Giant Cell Tumour, of which 6 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Tenosynovial Giant Cell Tumour come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Tenosynovial Giant Cell Tumour.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.